Abstract
REPORT HIGHLIGHTS
This report provides:
An overview of the global market for prescription generic drugs used in the
treatment of diabetes and devices and instruments used for diagnosis and
monitoring of diabetes, with a focus on Europe
Analyses of global market trends, with data from 2011, estimates for 2012, and
projections of compound annual growth rates (CAGRs) through 2017
Identification of markets based on epidemiological data and projections, plus
information on R&D trends and differential market potential on a
country-by-country basis
Discussion of healthcare policies, demographics, and the wider economic
environment
Examination of therapeutic categories, such as insulins and oral hypoglycemic
agents, and devices including blood glucose monitors and accessories
Patent analysis
Comprehensive company profiles of major players.
REPORT SCOPE
INTRODUCTION
STUDY GOALS AND OBJECTIVES
The aim of this report is to provide detailed market, technology, and industry
analyses to help readers quantify and qualify the market for drugs used in the
treatment of diabetes and for devices and instruments used in the diagnosis
and monitoring of diabetes. Special emphasis is given to major forces
contributing to the vigorous growth of the diabetes market. Important trends
are identified and sales forecasts by product categories and major country
markets are provided through 2017. These forecasts are based on
epidemiological data and projections, as well as on information about R&D
trends and differential market potential on a country-by-country basis.
Health care policies, demographics, and the wider economic environment are
also taken into account.
REASONS FOR DOING THE STUDY
It is widely recognized that the prevalence of the most common type of
diabetes mellitus, Type 2, is now reaching epidemic proportions all over the
world. Cases of Type 1 diabetes are also on the rise, although to a less
spectacular degree. These trends are of great concern, not only to the
individuals affected, but also to governments and providers of health care.
Indeed, the economic consequences of diabetes are vast, involving not only the
direct burden of managing the disease but also the common and often
catastrophic complications such as cardiovascular disease, peripheral
neuropathy, and blindness.
Prompt diagnosis and effective treatment of diabetes are essential, not
optional, priorities for governments and health care agencies. The already
large market for diabetes monitoring and treatment will certainly grow in line
with increasing incidence and with improvements in diagnosis. Thus diabetes
is of great commercial significance to the suppliers of drugs used in
treatment and to the suppliers of devices needed for disease monitoring.
Among the information needs of companies in this field is an accurate and
up-to-date assessment of the current extent of the diabetes epidemic, its
likely evolution over the next five years, and the impact of drugs and
technical developments now in the pipeline.
SCOPE OF REPORT
This report discusses the implications of the above-mentioned trends in the
context of the current size and growth of the diabetes market, discussed both
in global terms and in terms of the most important national markets.
Companies in the relevant pharmaceutical and medical industries are discussed,
with profiles of the leaders and an update on merger and acquisition (M&A)
activity. Five-year global sales forecasts are provided for main drug and
device categories, and breakdowns are provided for several national markets.
A comprehensive refresher course on diabetes is provided as an appendix.
MARKET ANALYSES AND FORECASTS
The dimensions of the surging diabetes epidemic can be witnessed in stark
outline against previous smaller estimates only a few years back. Increased
awareness of this "modern plague" has led naturally to improved and more
frequent testing practices. This new awareness has also led to improved
treatment compliance by patients. Added to these are the more expensive
therapies and increased penetration of continuous glucose monitoring (CGM)
approaches, which all combine to build a public health menace of accelerating
proportions.
For the purpose of market analyses in this report, the global market is
defined as 13 countries which together make up over 80% of the total diabetes
universe. These countries are the U.S., Canada, Brazil, Mexico, China, India,
Japan, Russia, Germany, France, Italy, Spain and the U.K.
Market figures are based on revenues at the manufacturer level and are
projected at 2012-dollar value without attempting to predict the effect of
inflation/deflation. Therapeutic categories discussed include insulins and
oral hypoglycemic agents, devices including blood glucose monitors and
accessories, and software aids to self-management of diabetes by patients.
METHODOLOGY
Primary research for this report included interviews with leading individuals
in relevant companies and medical associations; primary sources of published
data include epidemiological and economic studies, company annual reports, SEC
filings, and government publications. Secondary sources consisted of
literature searches, industry journals, and other commercial publications.
Data for market estimates and forecasts were pooled from a range of sources,
critically assessed by BCC.
INTENDED AUDIENCE
This report is designed to satisfy the information needs of a wide variety of
individuals involved in the diabetes marketplace, including company senior
management executives seeking to base their strategic decisions on the best
available information with regard to market forces and trends. However, it is
also aimed at managers and executives in marketing, research, planning, and
sales departments who need readable, comprehensive, and up-to-date background
information on the marketplace in which they are operating.
INFORMATION SOURCES
Sources of information included marketing strategists, industry executives,
government and professional agencies, and surveys of physicians. Company
annual reports and SEC filings, journal articles, and data from health care
institutions were also mined, as well as publications of relevant associations
such as the International Diabetes Federation and the American and British
Diabetic Associations.
ANALYST CREDENTIALS
Paul Evers has been involved in analyzing pharmaceutical and medical markets
for 20 years. He is the author of previous reports on the diabetes
marketplace covering both therapeutic and monitoring aspects.
Table of Contents
Chapter- 1: INTRODUCTION - Complimentary
- STUDY GOALS AND OBJECTIVES
- REASONS FOR DOING THE STUDY
- SCOPE OF REPORT
- MARKET ANALYSES AND FORECASTS
- METHODOLOGY
- INTENDED AUDIENCE
- INFORMATION SOURCES
- ANALYST CREDENTIALS
- RELATED REPORTS
- BCC ONLINE SERVICES
- DISCLAIMER
Chapter- 2: SUMMARY
- THE DIABETES MARKET
- LEADING COMPANIES
Chapter- 3: OVERVIEW
- DIABETES BASICS
- STRUCTURE OF THE DIABETES MARKET
- DRIVERS FOR GROWTH
- CURRENT TREATMENT OF DIABETES
- REGIONAL SEGMENTATION
- THE DIABETES INDUSTRY
Chapter- 4: PRODUCTS AND SUPPLIERS
- INSULIN
- INSULIN DELIVERY
- ORAL HYPOGLYCEMIC DRUGS
- DIAGNOSIS AND MONITORING
- OTHER TESTING APPROACHES
Chapter- 5: NEW DEVELOPMENTS IN DIABETES
- APPROACHES BASED ON CURRENT TECHNOLOGY
- RADICAL APPROACHES
- THE IMPACT OF NEW DEVELOPMENTS ON THE DIABETES MARKET
Chapter- 6: THE GLOBAL DIABETES MARKET
- MARKET COMPONENTS
- SIZE
- MARKET ANALYSIS BY PRODUCT CATEGORY
- TRENDS
Chapter- 7: THE EUROPEAN MARKET
- FRANCE
- FRANCE'S PHARMACEUTICAL MARKET
- GERMANY
- GERMANY'S PHARMACEUTICAL MARKET
- ITALY
- ITALY'S PHARMACEUTICAL MARKET
- RUSSIA
- RUSSIA'S PHARMACEUTICAL MARKET
- SPAIN
- SPAIN'S PHARMACEUTICAL MARKET
- THE UNITED KINGDOM
- THE UNITED KINGDOM'S PHARMACEUTICAL MARKET
Chapter- 8: COMPANY PROFILES
- LEADING COMPANIES
- OTHER COMPANIES
Chapter- 9: APPENDIX I: ABOUT DIABETES
- BLOOD SUGAR REGULATION
- INSULIN
- TYPE 1 DIABETES
- TYPE 2 DIABETES
- GESTATIONAL DIABETES
- OBESITY-RELATED TYPE 2 DIABETES IN CHILDREN
- MATURE-ONSET DIABETES OF THE YOUNG (MODY)
- OTHER DIABETIC STATES
- DIAGNOSIS
- GLUCOSE TESTS
- OFFICIAL CRITERIA
- DIFFERENTIAL DIAGNOSIS
- CURRENT TREATMENT
- DIET
- MONITORING DIABETES
- GLYCATED HEMOGLOBIN (HBA1C)
- PREVALENCE OF DIABETES
- DIABETIC COMPLICATIONS
- INCREASED MORTALITY RISK
- METABOLIC SYNDROME
Chapter- 10: APPENDIX 2: GLOSSARY
List of Tables
- Summary Table : DIABETES MARKET BREAKDOWN BY REGIONS, THROUGH 2017
- Table 1 : GLOBAL AND REGIONAL DIABETES PREVALENCE, 2011 AND 2017
- Table 2 : TOTAL DIABETES MARKET IN 2012
- Table 3 : ADULT DIABETES MARKET BY REGION
- Table 4 : MAJOR BRANDS OF INSULIN
- Table 5 : INSULIN PENS
- Table 6 : INSULIN PUMPS
- Table 7 : SULFONYLUREAS
- Table 8 : ORAL HYPOGLYCEMICS
- Table 9 : INTERNATIONAL SUPPLIERS OF BLOOD LANCETS
- Table 10 : SELECTED COMPANIES DEVELOPING NONINVASIVE GLUCOSE MONITORING
- Table 11 : GLOBAL DIABETES MARKET, 2011
- Table 12 : GLOBAL SALES OF LEADING INSULIN PRODUCTS, 2011
- Table 13 : SALES OF OTHER ANTIDIABETIC DRUGS, 2011
- Table 14 : DIABETES MARKET BREAKDOWN BY REGION, THROUGH 2017
- Table 15 : LEADING SUPPLIERS OF GLUCOSE MONITORING PRODUCTS, 2011
- Table 16 : RISING PREVALENCE OF DIABETES BY REGION, THROUGH 2017
- Table 17 : TOTAL DIABETES MARKET FOR CANADA AND THE U.S., THROUGH 2017
- Table 18 : TOTAL DIABETES MARKET FOR MEXICO AND BRAZIL, THROUGH 2017
- Table 19 : MAJOR EUROPEAN ECONOMIES: TOTAL DIABETES MARKET, THROUGH 2017
- Table 20 : MAJOR ASIAN COUNTRIES: TOTAL DIABETES MARKET, THROUGH 2017
- Table 21 : PREVALENCE OF DIABETES IN FRANCE, THROUGH 2017
- Table 22 : FRANCE: DIABETES MEDICATIONS MARKET, THROUGH 2017
- Table 23 : FRANCE: DIABETES DEVICES MARKET, THROUGH 2017
- Table 24 : PREVALENCE OF DIABETES IN GERMANY, THROUGH 2017
- Table 25 : GERMANY: DIABETES MEDICATIONS MARKET, THROUGH 2017
- Table 26 : GERMANY: DIABETES DEVICES MARKET, THROUGH 2017
- Table 27 : PREVALENCE OF DIABETES IN ITALY, THROUGH 2017
- Table 28 : ITALY: DIABETES MEDICATIONS MARKET, THROUGH 2017
- Table 29 : ITALY: DIABETES DEVICES MARKET, THROUGH 2017
- Table 30 : PREVALENCE OF DIABETES IN RUSSIA, THROUGH 2017
- Table 31 : RUSSIA: DIABETES MEDICATIONS MARKET, THROUGH 2017
- Table 32 : RUSSIA: DIABETES DEVICES MARKET, THROUGH 2017
- Table 33 : PREVALENCE OF DIABETES IN SPAIN, THROUGH 2017
- Table 34 : SPAIN: DIABETES MEDICATIONS MARKET, THROUGH 2017
- Table 35 : SPAIN: DIABETES DEVICES MARKET, THROUGH 2017
- Table 36 : PREVALENCE OF DIABETES IN THE U.K., THROUGH 2017
- Table 37 : U.K.: DIABETES MEDICATIONS MARKET, THROUGH 2017
- Table 38 : U.K.: DIABETES DEVICES MARKET, THROUGH 2017
- Table 39 : NOVO NORDISK DIABETES PRODUCT PIPELINE
- Table 40 : DIABETES PRODUCTS IN DEVELOPMENT BY TAKEDA
- Table 41 : GLOSSARY
Global Markets for Diabetes Therapeutics and Diagnostics -- Focus on Europe published by BCC Research in January 1, 2013. This report consists of 140 Pages and the price starts from US $ 4400.
